The current issue of the American Journal of Psychiatry carries a meta-analysis of different psychosocial interventions for the treatment of substance abuse (Dutra L et al., Am J Psychiatry 2008 165: 179-187). This review focuses specifically on techniques for treating abusers of cannabis, cocaine, and opiates. What works the best, and what techniques can you bring into your practice.
Psychostimulants are commonly added to antidepressants in order to augment their effects, but most of the clinical trials have been either open or small controlled trials. In what may be the largest trial done to date, these investigators (who received funding from Janssen-Ortho, the maker of Concerta) randomized 145 depressed patients...
The U.S. Food and Drug Administration (FDA) warned healthcare professionals that patients taking antiepileptic drugs (AEDs) have twice the risk of suicidal behavior or ideation compared with those taking placebo.
Dr. Willenbring, there are now several medications with evidence for treating alcohol problems. It gets confusing to know which ones to use in which situations.
In this article, we’ll review the clinical data on three of the most frequently used of the novel anticonvulsants: Trileptal (oxcarbazepine), Topamax (topiramate), and Neurontin (gabapentin). We cover Lamictal in this month’s expert interview with Nassir Ghaemi.
Over the past couple of decades, psychiatry has adopted a number of anticonvulsants that effectively treat psychiatric conditions. The “kindling hypothesis” has provided a rationale for their increasing use, but what is the evidence behind this theory, and is it actually applicable for psychiatric practice?
In a ruling certain to make psychiatrists and their patients happy, the DEA has finally said that doctors may give patients 90 days worth of prescriptions for schedule II controlled substances, which includes stimulants and narcotics.
In a multi-center study conducted in Great Britain and Australia, 86 adults with mental retardation (IQ < 75) and aggressive behavior were randomized to double-blind treatment with Risperdal (mean dose, 1.8 mg/day), Haldol (mean dose, 2.9 mg/day), or placebo. The primary outcome was score on the modified overt aggression scale (MOAS) at 4 weeks.
The North American Prodrome Longitudinal Study is a consortium of 8 academic centers (all but one in the U.S.) seeking to develop predictors of the development of psychosis in young patients who present with prodromal symptoms.